

**EVAN PAUL KRANSDORF, M.D., PH.D.**

**CURRICULUM VITAE**

April 14<sup>th</sup>, 2021

**PROFESSIONAL CONTACT INFORMATION**

Business Address: Cedars-Sinai Medical Center  
8700 Beverly Blvd  
Los Angeles, CA 90048

California Heart Center  
8670 Wilshire Blvd, 2<sup>nd</sup> Floor  
Beverly Hills, CA 90211

Phone: (310) 248-8300  
Fax: (310) 248-8333  
Email: [evan.kransdorf@cshs.org](mailto:evan.kransdorf@cshs.org)

**EDUCATION**

**Undergraduate**

University of Virginia, Charlottesville, Virginia 8/1995 – 5/1999  
B.S. in Chemistry, with Highest Distinction

**Medical Education**

Virginia Commonwealth University School of Medicine, Richmond, Virginia 9/1999 – 5/2006  
M.D. /Ph.D. Program  
Ph. D. in Microbiology/Immunology  
Concentration in Molecular Biology and Genetics

**Residency**

Duke University Medical Center, Durham, North Carolina 6/2006 – 6/2009  
Resident, Internal Medicine

**General Cardiology Fellowship**

Duke University Medical Center, Durham, North Carolina 7/2009 – 6/2010  
Fellowship, Cardiovascular Disease

Cedars-Sinai Medical Center, Los Angeles, California 7/2011 – 6/2012  
Fellowship, Advanced Heart Failure and Heart Transplantation

Mayo Clinic Arizona, Scottsdale, Arizona 7/2012 – 2/2015  
Fellowship, Cardiovascular Diseases

University of Washington (Online) 9/2014 – 4/2015  
Certificate Program in Statistical Programming with R

**LICENSURE:**

National Provider Identifier (NPI), 1194917534	2007 –
North Carolina License, #2009-00021	2009 – 2010
Arizona Medical License, # 43348	2010 –
California Medical License, # A116087	2011 –
Drug Enforcement Administration (DEA), BA BC8507420	2014 –

**BOARD CERTIFICATION:**

Internal Medicine, American Board of Internal Medicine	2009 – 2019
Cardiovascular Disease, American Board of Internal Medicine	2014 – 2024
Advanced Heart Failure/Transplant Cardiology, American Board of Internal Medicine	2016 – 2026

**PROFESSIONAL EXPERIENCE:**

**Present Position:**

3/2016 – Attending Physician, California Heart Center, Cedars-Sinai Heart Institute, Los Angeles, California

**Previous Position:**

12/2009 – 6/2010 Physician, Hospital Internal Medicine, Medical Officer of the Day, Veteran’s Administration Hospital, Durham, North Carolina

7/2010 – 6/2011 Physician, Hospital Internal Medicine, Desert Vista Medical Associates, Banner Good Samaritan Hospital, Phoenix, Arizona

11/2014 – 6/2015 Instructor in Medicine, Mayo Clinic College of Medicine, Phoenix, Arizona

5/2015 – 3/2016 Attending Physician/Senior Associate Consultant, Division of Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, Arizona

7/2015 – 3/2016 Assistant Professor of Medicine, Mayo Clinic College of Medicine, Phoenix, Arizona

**PROFESSIONAL ACTIVITIES:**

**CSMC:**

2011 – Heart Transplant Executive Committee  
2013 – Heart Transplant Selection Committee  
2017 – California Heart Center CME Committee  
2017 – Clinical Performance Committee  
2018 – OPTN Histocompatibility Committee  
2021 – AHD Research/Publications Oversight Committee

**Other Committee Services:**

2007 – 2008 Duke Internal Medicine Residency Council  
2009 – 2010 Cardiovascular Medicine Fellowship Selection Committee  
2013 – 2015 Cardiovascular Diseases Fellowship Selection Committee  
2014 – 2015 Representative of the Junior Faculty and Trainee Council to the Registries and Databases Committee, International Society for Heart and Lung Transplantation  
2017 – 2018 JFTC/Governance Committee

**Professional Associations/Society Memberships:**

2012 – Member, American College of Cardiology  
2013 – Member, American Society of Transplantation  
2013 – Member, International Society for Heart and Lung Transplantation  
2016 – 2022 Chair, Junior Faculty and Trainee Council, International Society for Heart and Lung Transplantation

**Editorial Services:**

2015 – Reviewer, Journal of Heart and Lung Transplantation  
4/2015 Abstract reviewer and poster judge, ISHLT 35th Annual Meeting and Scientific Sessions, Nice, France  
4/2016 Abstract reviewer and poster judge, ISHLT 35th Annual Meeting and Scientific Sessions, Nice, France  
2016 – Reviewer, Transplantation Journal

**Consulting Services:**

2008 Assistant Chief Resident, Durham Regional Hospital  
2014 – 2015 Co-Chief Fellow, Cardiovascular Diseases Fellowship

**HONORS AND SPECIAL AWARDS:**

1998 University of Virginia, Distinguished Majors Program  
1998 University of Virginia, Summer Undergraduate Research Fellowship  
1999 University of Virginia, Distinguished Majors Program  
1999 Virginia Commonwealth University School of Medicine, Dean's Scholarship  
1999 Immunology Course Award for Highest Grade in the Class  
2006 Duke University Medical Center, Barton F. Haynes Research Award  
2008 Clinical Research Poster Award, American College of Physicians  
2008 North Carolina Chapter  
2014 Mayo Clinic Arizona, 1st Place, Oral Presentation in Clinical Research  
2014 Joint Statistical Meetings 2014, Best Poster Award  
2015 International Society for Heart and Lung Transplantation, Transplant Registry Early Career Award  
2017 Cedars-Sinai Heart Institute, Dr. Jon A. Kobashigawa Award for Excellence in Education and Dedication of the Advanced Heart Disease Fellows Award

**RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:**

**Active/Ongoing:**

**Internally Funded** **Kransdorf (PI)** **12/20/18 – Present**  
**Immunologic Risk Study.** This is a pilot study to apply the novel technique of B-cell receptor repertoire sequencing to patients with heart failure and allosensitization. Samples will be drawn before or after an

immunologic stimulus to determine changes in the B-cell repertoire in response to implantation of a left ventricular assist device or desensitization therapies.

Role: PI

**One Legacy Foundation/Baylor University      Kransdorf (Site PI)      06/01/19 – Present**  
**Transplant of Redeemed Organs by Judicious Administration of New Direct Acting Antivirals for Hepatitis-C Heart Recipients (TROJAN-C).** This prospective, multi-center, open-label clinical trial will utilize Hepatitis C virus (HCV) - Positive donors for heart transplantation in HCV-negative recipients.

**NIH      Kransdorf (Site PI)      05/18/18 – Present**  
**Dilated Cardiomyopathy Precision Medicine Study.** This is a NIH funded study to assess the frequency of genetic mutations in patients with dilated cardiomyopathy and their family members.

Role: Co-I

**NIH/Duke University      Kransdorf (Site PI)      11/01/17 – Present**  
**Entresto™ (LCZ696) In Advanced Heart Failure (Life Study).** The purpose of this study is to evaluate the effects of LCZ696 (Entresto) compared to valsartan by evaluating NT-proBNP levels. The hypothesis is that patients with symptomatic heart failure due to left ventricular systolic dysfunction, treatment with LCZ696 for 24 weeks will improve NT-proBNP levels. The study is a randomized, double-blinded trial of advanced heart failure subjects.

#### **Completed:**

**Genzyme      Kobashigawa (PI)      07/01/2018 – 07/01/2021**  
**A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (ATG):** A 12-month, single center, randomized, open-label study of efficacy comparing immediate treatment with and without Thymoglobulin® 1.5 mg/kg/d for 5 consecutive days in heart transplant recipients. The purpose of this study is to definitively establish Thymoglobulin's potential efficacy in preventing cardiac allograft vasculopathy.

Role: Co-Investigator

**TransMedics      Esmailian (PI)      09/11/2019 – 09/10/2022**  
**OCS-CAR-121918 - Continued Access Protocol to collect additional evidence to evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Heart For Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation (Heart EXPAND CAP**

Role: Co-Investigator

**NIH ALL-IN Study/1U01AI136816-01      Patel(Site PI)      05/01/2018– 04/30/2020**  
**Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab.** The primary objective of the study is to compare the efficacy of standard of care triple maintenance immunosuppression plus tocilizumab treatment versus standard of care triple maintenance immunosuppression plus placebo on outcomes as defined by a composite 1 year post-transplant endpoint of a) detection of donor-specific antibodies (DSA), b) acute cellular rejection (ACR), c) antibody mediated rejection (AMR), d) hemodynamic compromise (HDC) rejection in absence of biopsy or histological rejection, e) death, and f) retransplantation.

Role: Co-Investigator

## **RESEARCH FOCUS AND INTERESTS:**

My passion to perform research stems directly from the need to answer questions I encounter as a practicing heart failure and transplant clinician. My interest in research originates from my background in basic science. My approach to research stems from my training as a cardiologist where an evidence-based approach to clinical care is emphasized. I have participated as a site Principal Investigator and Co-Instigator on a number of clinical trials in transplantation.

## **INVITED LECTURES AND PRESENTATIONS:**

1. “Mechanisms of immune activation with brain death: Can this be modified?” Presented at the American Society of Transplantation “Cutting Edge of Transplantation” Meeting, Phoenix, Arizona. February 26, 2016.
2. “Genomics: What do I have to know and how will it affect my practice?” Session Chair. Presented at the International Society for Heart and Lung Transplantation Annual Meeting and Scientific Sessions, Washington, D.C. April 27, 2016.
3. The Risk of Naïve vs Memory Patients Awaiting Heart Transplantation: Does It Make a Difference in Post-Transplant Outcomes? Presented at the International Society of Heart & Lung Transplantation. April 6, 2017
4. The Ultimate Calculated Panel Reactive Antibody Value Predicts Mortality After Heart Transplantation. Presented at the American Transplant Congress. April 20, 2017
5. “Frailty Measures in End Organ Failure: What Measures Up? Presented at American Transplant Congress 2017 Annual Meeting, Chicago, IL April 29, 2017
6. “New Therapies for Congestive Heart Failure and Diastolic Heart Failure”, Presented at the Fountain Valley, California Regional Hospital & Medical Center. May 5, 2017
7. “Cardiomyopathy/Heart Failure: The Most Up to Date – State of the Art Ways to Treat Heart Failure and Maintain Quality of Life” AHMC Anaheim Regional Medical Center, Anaheim, CA. September 12, 2017
8. “New Imaging Modalities – A Game Changer for Heart Failure Diagnostics?”, Optimal Care and New Therapies in Advanced Heart Disease, Santa Barbara, California. November 3, 2018.
9. “Balancing Benefit and Adversity: A Review of Hep-C Donor Hearts & Outcomes”, Presented at Success with Failure: The Art & Science of Heart Failure Management”, Marina Del Rey, California. February 1st, 2019.
10. “Advances in Heart Transplantation,” Presented at Trauma Nurse’ Association Meeting, Long Beach, California. July 9th, 2019.
11. “New Imaging Modalities – A Game Changer for Heart Failure Diagnostics?”, Optimal Care and New Therapies in Advanced Heart Disease, Las Vegas, Nevada. September 7, 2019.

## **TEACHING ACTIVITIES:**

### Non-Clinical Teaching

1. “The new UNOS donor heart allocation proposal is fair!” Presented at the Cedars-Sinai “Controversies & Advances In The Treatment of Cardiovascular Disease”, Beverly Hills, California. November 17, 2016

## **BIBLIOGRAPHY/PUBLICATIONS**

### **Research Papers – Peer Reviewed:**

1. Basu P, Sargent TG, Redmond LC, Aisenberg JC, **Kransdorf EP**, Wang SZ, Ginder GD, Lloyd JA. Evolutionary conservation of KLF transcription factors and functional conservation of human  $\gamma$ -globin gene regulation in chicken. *Genomics* 2004; 84(2): 311– 319.
2. **Kransdorf EP**, Wang SZ, Zhu SZ, Langston TB, Rupon JW, Ginder GD. MBD2 is a critical component of a methylcytosine binding protein complex isolated from primary erythroid cells. *Blood* 2006; 108(8): 2836-2845.
3. Leonardi RA, **Kransdorf EP**, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. *Circulation: Cardiovascular Interventions* 2010; 3(2): 97-104.
4. **Kransdorf EP**, Arcasoy MO. Unraveling a sticky paradox. *American Journal of Medicine* 2010; 123(5): 417-9.
5. Crowley MJ, Barkauskas CE, Srygley FD, **Kransdorf EP**, LeBlanc TW, Simel DL, McNeill DB. A comparative resident site visit project: A novel approach for implementing programmatic change in the duty hours era. *Academic Medicine* 2010; 85(7): 1140-1146.
6. **Kransdorf EP**, Kittleson MK. Dissecting the “CHF Admission”: an evidence-based review of the evaluation and management of acute decompensated heart failure for the hospitalist. *Journal of Hospital Medicine* 2012; 7(5): 439-445.
7. **Kransdorf EP**, Kobashigawa JA. Genetic and genomic approaches to the detection of heart transplant rejection. *Personalized Medicine* 2012; 9(7); 693-705.
8. **Kransdorf EP**, Czer LSC, Luthringer DJ, Patel JK, Montgomery SP, Velleca A, Mirocha J, Zakowski PC, Zabner R, Gaultier CR, Qvarnstrom Y, Benedict T, Steurer F, Bosserman E, Paddock CD, Rafiei M, Kobashigawa JA. Heart transplantation for Chagas cardiomyopathy in the United States. *American Journal of Transplantation* 2013; 13(12): 3262-8.
9. **Kransdorf EP**, Kittleson MM, Kobashigawa JA. Atypical hemolytic-uremic syndrome immediately after heart transplantation. *Journal of Heart and Lung Transplantation* 2014; 33(6): 664-5.

10. **Kransdorf EP**, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and heart transplantation. *Current Opinion in Infectious Diseases* 2014; 27(5): 418-24.
11. **Kransdorf EP**, Stehlik J. Donor evaluation in heart transplantation: the end of the beginning. *Journal of Heart and Lung Transplantation* 2014; 33(11): 1105-13.
12. Hakim FA, **Kransdorf EP**, Abudiab MM, Sweeney JP. Paradoxical coronary artery embolism - a rare cause of myocardial infarction. *Heart Views* 2014; 15(4): 124-6.
13. **Kransdorf EP**, Kransdorf LN, Fortuin FD, Sweeney JP, Wilansky S. Stepwise progression of right-to-left atrial shunting due to the combination of patent foramen ovale and tricuspid regurgitation. *Texas Heart Institute Journal* 2016; 43(2): 171-4.
14. Morris AA, **Kransdorf EP**, Coleman BL, Colvin M. Racial and ethnic disparities in outcomes after heart transplantation: are we closing the gap? *Journal of Heart and Lung Transplantation* 2016; 35(8): 953-61.
15. **Kransdorf EP**, Fishbein MC, Czer LSC, Patel JK, Velleca A, Tazelaar HD, Roy RR, Steidley DE, Kobashigawa JA, Luthringer DJ. Pathology of Chronic Chagas Cardiomyopathy in the United States: A detailed review of 13 cardiectomy cases. *American Journal of Clinical Pathology* 2016; 146(2): 191-8.
16. Schleifer JW, Mookadam F, **Kransdorf EP**, Nanda U, Adams JC, Cha S, Pajaro OE, Steidley DE, Scott RL, Carvajal T, Saadiq RA, Srivathsan K. Effect of continued cardiac resynchronization therapy on ventricular arrhythmias after left ventricular assist device implantation. *American Journal of Cardiology* 2016; 118(4):556-9.
17. **Kransdorf EP**, Kobashigawa JA. Biomarkers for cardiac allograft vasculopathy: Still searching after all these years. *Transplantation* 2016; *in press*.
18. **Kransdorf EP**, Pando MP. Calculated panel reactive antibody with decimals: a refined metric of access to transplantation for highly sensitized candidates. *Human Immunology*; *in press*.
19. **Kransdorf EP**, Kittleson MM, Patel JK, Pando M, Steidley DE, Kobashigawa JA. Calculated panel reactive antibody predicts outcomes on the heart transplant waiting list. *Journal of Heart and Lung Transplantation*

20. **Kransdorf EP**, Loghmanpour NA, Kanwar MK, Temkit MH, Stehlik J. Prediction model for cardiac allograft vasculopathy: comparison of three multivariate methods. *Clinical Transplantation*
21. **Kransdorf EP**, Pando MJ, Gragert L, Kaplan B. HLA Population Genetics in Solid Organ Transplantation. *Transplantation* 2017
22. Miller RJH, Thomson L, Levine R, Dimbil SJ, Patel J, Kobashigawa JA, **Kransdorf E**, Li D, Berman DS, Tamarappoo B. Quantitative myocardial tissue characterization by cardiac magnetic resonance in heart transplant patients with suspected cardiac rejection. *Clin Transplant*. 2019. Epub 2019/08/31.
23. Miller RJ, Kwiecinski J, Shah KS, Eisenberg E, Patel J, Kobashigawa JA, Azarbal B, Tamarappoo B, Berman DS, Slomka PJ, **Kransdorf E**, Dey D. Coronary computed tomographic angiography quantitative plaque analysis improves detection of early cardiac allograft vasculopathy: a pilot study. *American Journal of Transplantation*. 2019. Epub 2019/11/24.
24. Kaur N, Pinelli D, **Kransdorf EP**, Pando MJ, Smith G, Murphey CL, Kamoun M, Bray RA, Tambur A, Gragert L. A blueprint for electronic utilization of ambiguous molecular HLA typing data in organ allocation systems and virtual crossmatch. *Hum Immunol*. 2020 Feb-Mar;81(2-3):65-72.
25. Zhang X, **Kransdorf E**, Levine R, Patel JK, Kobashigawa JA. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients. *Hum Immunol*. 2020 Jul;81(7):330-336.
26. Miller RJH, Cadet S, Pournazari P, Pope A, **Kransdorf E**, Hamilton MA, Patel J, Hayes S, Friedman J, Thomson L, Tamarappoo B, Berman DS, Slomka PJ. Quantitative Assessment of Cardiac Hypermetabolism and Perfusion for Diagnosis of Cardiac Sarcoidosis. *J Nucl Cardiol*. 2020 May 27.
27. **Kransdorf EP**, Pando MJ, Stewart D, Lindblad K, Bray R, Murphey C, Kaur N, Patel JK, Kim I, Zhang X, Maiers M, Kobashigawa JA, Gragert L. Stem cell donor HLA typing improves CPRA in kidney allocation. *Am J Transplant*. 2020 Jun 18.
28. Vaidya G, Czer LSC, Kobashigawa J, Kittleson M, Patel J, Chang D, **Kransdorf E**, Shikhare A, Tran H, Vo A, Ammerman N, Huang E, Zabner R, Jordan S. Successful Treatment of severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. *Transplant Proc*. 2020 Jun 7:S0041-1345(20)32575-6.



29. Kobashigawa J, Shah P, Joseph S, Olymbios M, Bhat G, Dhital K, Eisen H, **Kransdorf E**, Patel J, Skorka R, Pinney S, Wilson ME, Hall S; Heart Frailty Workgroup. Frailty in Heart Transplantation: Report from the Heart Workgroup of a Consensus Conference on Frailty. *Am J Transplant*. 2020 Jul 13.
30. Coutance G, **Kransdorf E**, Bonnet G, Loupy A, Kobashigawa J, Patel JK. Statistical performance of sixteen post-transplant risk scores in a contemporary cohort of heart transplant recipients. *Am J Transplant*. 2020 Jul 26.
31. Ivey-Miranda JB, Kunnirickal S, Bow L, Maulion C, Testani JM, Jacoby D, **Kransdorf EP**, Bellumkonda L. Differential Impact of Class I and Class II Panel Reactive Antibodies on Post-Heart Transplant Outcomes. *J Card Fail*. 2020 Aug 1;S1071-9164(20)30894-0. doi: 10.1016/j.cardfail.2020.07.012. Online ahead of print. PMID: 32750489
32. Ivey-Miranda JB, Kunnirickal S, Bow L, Maulion C, Testani JM, Jacoby D, **Kransdorf EP**, Bellumkonda L. Differential Impact of Class I and Class II Panel Reactive Antibodies on Post-Heart Transplant Outcomes. *J Card Fail*. 2021 Jan;27(1):40-47. doi: 10.1016/j.cardfail.2020.07.012. Epub 2020 Aug 1. PMID: 32750489.
33. Kobashigawa J, Shah P, Joseph S, Olymbios M, Bhat G, Dhital K, Eisen H, **Kransdorf E**, Patel J, Skorka R, Pinney S, Wilson ME, Hall S; Heart Frailty Workgroup. Frailty in heart transplantation: Report from the heart workgroup of a consensus conference on frailty. *Am J Transplant*. 2021 Feb;21(2):636-644. doi: 10.1111/ajt.16207. Epub 2020 Aug 29. PMID: 32659872.
34. Coutance G, **Kransdorf E**, Bonnet G, Loupy A, Kobashigawa J, Patel JK. Statistical performance of 16 posttransplant risk scores in a contemporary cohort of heart transplant recipients. *Am J Transplant*. 2021 Feb;21(2):645-656. doi: 10.1111/ajt.16217. Epub 2020 Sep 5. PMID: 32713121.
35. Patel JK, Coutance G, Loupy A, Dilibero D, Hamilton M, Kittleson M, **Kransdorf E**, Azarbal B, Seguchi O, Zhang X, Chang D, Geft D, Czer L, Varnous S, Kobashigawa JA. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. *Am J Transplant*. 2020 Nov 29. doi: 10.1111/ajt.16420. Epub ahead of print. PMID:33251691.
36. Vaidya G, Czer LSC, Kobashigawa J, Kittleson M, Patel J, Chang D, **Kransdorf E**, Shikhare A, Tran H, Vo A, Ammerman N, Huang E, Zabner R, Jordan S. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. *Transplant Proc*. 2020 Nov;52(9):2711-2714. doi: 10.1016/j.transproceed.2020.06.003. Epub 2020 Jun 7. PMID: 32563584; PMCID: PMC7275980.
37. Vaidya GN, Czer LSC, Luthringer D, Kittleson M, Patel J, Chang DH, **Kransdorf E**, Geft D, Azarbal B, Hamilton M, Kobashigawa J. Heart Transplantation for Giant Cell Myocarditis: A Case Series.

Transplant Proc. 2021 Jan-Feb;53(1):348-352. doi: 10.1016/j.transproceed.2020.10.047. Epub 2020 Dec 29. PMID: 33384178.

38. **Kransdorf EP**, Pando MJ, Stewart D, Lindblad K, Bray R, Murphey C, Kaur N, Patel JK, Kim I, Zhang X, Maiers M, Kobashigawa JA, Gragert L. Stem cell donor HLA typing improves CPRA in kidney allocation. *Am J Transplant*. 2021 Jan;21(1):138-147. doi: 10.1111/ajt.16156. Epub 2020 Jul 13. PMID: 32558252.
39. Vaidya GN, Patel JK, Kittleson M, Chang DH, **Kransdorf E**, Geft D, Czer L, Vescio R, Esmailian F, Kobashigawa JA. Intermediate-term Outcomes of Heart Transplantation for Cardiac Amyloidosis in the Current Era. *Clin Transplant*. 2021 Apr 7:e14308. doi: 10.1111/ctr.14308. Epub ahead of print. PMID: 33825224.

**Research Papers – Peer Reviewed (In Press): None**

**Research Papers – Peer Reviewed (Submitted): None**

**Chapters:**

1. **Kransdorf EP**, Steidley DE. “Chapter 17: Inhibition of the sympathetic nervous system,” in *Heart Failure: A Comprehensive Guide to Pathophysiology and Clinical Care*, editor Howard Eisen (Springer, 2016).
2. **Kransdorf EP**, Kittleson MM. “Chapter 24: Heart transplantation and left ventricular assist devices in cancer survivors,” in *Cardio-Oncology: Principles, Prevention and Management*, editors Roberta Gottlieb and Puja Mehta (Elsevier, 2016).
3. **Kransdorf EP**, Kobashigawa JA. “Chapter 44: Heart Transplantation,” in *Heart Failure: A Companion to Braunwald’s Heart Disease*, editors G. Michael Felker and Douglas L. Mann (Elsevier, 2019).

**Letters:**

1. **Kransdorf EP**, Stehlik J. Reply: Heart donation and the Grinch effect. *Journal of Heart and Lung Transplantation* 2014; 34(1): 137.

**Reviews: None**

**Editorials:**

1. **Kransdorf EP**, Steidley DE. A Complicated Case of Dyspnea. *Cardiosource: Sleep Apnea Community*. October 2, 2013. Retrieved 10/05/2013 from <http://apnea.cardiosource.org/Case-Challenges/2013/10/Complicated-Cause-of-Dyspnea.aspx>
2. **Kransdorf EP**, Kobashigawa JA. The heart track: A summary of the CEOT Breakout Sessions. *American Society of Transplantation President’s Blog*. April 27, 2016. Retrieved 04/30/2016 from <https://www.myast.org/about-ast/president-blog>

## Papers in Preparation (Research Completed): None

### Abstracts:

1. Basu P, Aisenberg J, Sargent T, Wang SZ, **Kransdorf E**, Ginder GD, Lloyd JA. The gamma-globin CACCC element in the regulation of human gamma to beta globin switching in a chicken model system. *Blood Cells, Molecules, and Diseases* 2003; 31: 129.
2. **Kransdorf EP**. Purification and characterization of a methyl-DNA binding protein complex from primary erythroid cells. Ph.D. Dissertation. Virginia Commonwealth University, 2004.
3. Ginder G, **Kransdorf E**, Rupon J, Wang SZ. DNA methylation and maintenance of embryonic globin gene silencing. *Blood Cells, Molecules, and Diseases* 2005; 34: 89.
4. **Kransdorf E**, Wang SZ, Ginder GD. Purification and characterization of a methyl-DNA binding protein complex from primary erythroid cells. *Blood Cells, Molecules, and Diseases* 2005; 34: 98-99.
5. **Kransdorf EP**, Velazquez EJ. Anemia in heart failure: a practical review. Presented at the American College of Physicians Scientific Sessions for North Carolina chapter, Durham, North Carolina. January 2008.
6. Leonardi R, **Kransdorf E**, Simel D, Wang D. Abstract 4157: Alcohol septal ablation is not associated with an increase in sudden or all-cause mortality in obstructive hypertrophic cardiomyopathy: a meta-analysis. *Circulation* 2009; 120: S915.
7. Kansara P, **Kransdorf E**, Kittleson M, Patel J, Coleman B, Jamero G, Runyan C, Olay C, Jocson R, Czer L, Trento A, Kass R, Esmailian F, Kobashigawa J, Moriguchi J. Improved outcomes in “Crash and Burn” patients through BiVAD support. *Journal of Heart and Lung Transplantation* 2012; 31: S267-S268.
8. **Kransdorf EP**, Czer LS, Patel JK, Zakowski PC, Gaultier CR, Zabner R, Chang DH, Kittleson MM, Kobashigawa JA. High prevalence and reactivation of Chagas Disease in heart transplant recipients. *American Journal of Transplantation* 2012; 12 (supplement 3): 477-478.
9. **Kransdorf E**, Moriguchi J, Kittleson M, Runyan C, Olay C, Jocson R, Czer L, Trento A, Esmailian F, Kobashigawa J. The use of the model for end-stage liver disease score predicts 90-day mortality in patients undergoing HeartMate II implantation. *Circulation* 2012; 126: A9724.
10. Moriguchi J, Kansara P, **Kransdorf E**, Kittleson M, Patel J, Runyan C, Olay C, Jocson R, Czer L, Esmailian F, Kobashigawa J. Biventricular assist device may be superior to left ventricular assist device for crash and burn patients. *Circulation* 2012; 126: A9934.
11. **Kransdorf E**, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Czer L, Hage A, Zakowski P, Kobashigawa J. High rate of reactivation of Chagas disease after heart transplantation in the United States. *Journal of Heart and Lung Transplantation* 2013; 32: S130
12. Carvajal T, **Kransdorf EP**, Kasper DL, Scott RL, Steidley DE, Gopalan RS, Kalya AV, Arabia FA, Pajaro OE. Human leukocyte antigen mismatch in heart transplants continues to predict outcomes in modern era of immunosuppression. *Journal of Heart and Lung Transplantation* 2013; 32: S213.
13. **Kransdorf E**, Chang D, Ro C, Reznik R, Yu R, Gordon O, Esmailian F, Patel J, Kittleson M, Kobashigawa J. Familial Paraganglioma Induced Cardiomyopathy Requiring Heart Transplantation. J

Heart and Lung Transplant. 2013; 32(4).

14. **Kransdorf E**, Chang DH, Ro C, Reznik R, Yu R, Gordon O, Esmailian F, Patel J, Kittleson M, Kobashigawa J. Familial paraganglioma induced cardiomyopathy requiring heart transplantation. Presented at the International Society for Heart and Lung Transplantation, 33<sup>rd</sup> Annual Meeting and Scientific Sessions, Montreal, Quebec, Canada. April 2013.
15. **Kransdorf EP**, Carvajal T, Steidley DE, Leis FJ, Adams RH, Balan V, Bordner A, Pajaro OE. A novel measure of recipient-donor HLA mismatch predicts allograft rejection after heart transplantation. Presented at the American Society for Histocompatibility and Immunogenetics, 39th Annual Meeting, Chicago, Illinois. November 2013.
16. **Kransdorf E**, Kittleson M, Coleman B, Hoffman D, Berkman S, Ramzy D, Steidley DE, Kobashigawa J. Atypical Hemolytic-Uremic Syndrome Immediately Following Heart Transplantation. *J Heart Lung Transplant*. 2014; 33(6): 664-665.
17. **Kransdorf EP**, Fishbein MC, Czer LSC, Patel JK, Velleca A, Kobashigawa JA, Luthringer DJ. Pathology of chronic Chagas cardiomyopathy in the United States a detailed review of 12 cardiectomy cases. *Modern Pathology* 2014; 27: 91A.
18. **Kransdorf EP**, Carvajal T, Cheng M, Steidley DE, Scott RL, Leis JF, Adams RH, Bordner A, Balan V, Pajaro OE. A novel allele-based measure of HLA mismatch predicts treated rejection after heart transplant. *Journal of Heart and Lung Transplantation* 2014; 33(4 Supplement): S144-145.
19. Carvajal T, **Kransdorf EP**, Cheng M, Steidley DE, Scott RL, Bordner A, Balan V, Pajaro OE. Effect of match for ethnicity on immunologic events after heart transplantation: an analysis of the UNOS/OPTN database. *Journal of Heart and Lung Transplantation* 2014; 33(4 Supplement): S91.
20. Morris A, Kalogeropoulos A, **Kransdorf E**, Owen M, Cole RT, Brown J, Gupta D, Laskar S, Smith A, Butler J. Race/ethnic differences in the epidemiology of graft failure in a contemporary cohort. *Journal of Heart and Lung Transplantation* 2014; 33(4 Supplement): S90.
21. **Kransdorf E**, Cheng M, Steidley D, Scott, R, Pajaro O. Does antibody induction immunotherapy prevent the development of cardiac allograft vasculopathy? *American Journal of Transplantation* 2014; 14 (3 Supplement): 58.
22. **Kransdorf EP**, Carvajal T, Cheng MR, Steidley DE, Leis FJ, Adams RH, Bordner A, Scott RL, Balan V, Pajaro OE. Recipient-donor mismatch for HLA-B protects against the development of cardiac allograft vasculopathy. Presented at the American Society of Transplantation, "Cutting Edge of Transplantation 2014" Meeting, Chandler, Arizona. February 2014.
23. **Kransdorf E**, Kittleson M, Coleman B, Hoffman D, Berkman S, Ramzy D, Steidley D, Kobashigawa J. Atypical hemolytic-uremic syndrome immediately following heart transplantation. Presented at the International Society for Heart and Lung Transplantation, 34th Annual Meeting and Scientific Sessions, San Diego, California. April 2014.
24. Cheng M, Dueck A, **Kransdorf EP**, Pajaro OE, Chang YH. Rate data modeling: Using the Organ Procurement and Transplantation Network/United Network for Organ Sharing Database. Presented at the Joint Statistical Meetings, Boston, Massachusetts. August 2014.
25. **Kransdorf EP**, Gragert L, Che

26. ng M, Steidley DE, Scott RL, Pando MJ, Maiers M, Pajaro OE. A novel human leukocyte antigen score improves prediction for rejection after heart transplant. *Journal of Heart and Lung Transplantation* 2015; 34 (4 Supplement): S114.
27. Schleifer JW, Mookadam F, **Kransdorf E**, Nanda U, Cha S, Pajaro OE, Steidley DE, Scott RL, Adams JC, Saadiq R, Carvajal TC, Srivathsan K. Cardiac resynchronization therapy does not reduce ventricular arrhythmias after left ventricular assist device implantation. *Journal of Heart and Lung Transplantation* 2015; 34 (4 Supplement): S199.
28. Gray EB, Benedict T, Rivera H, Huprikar S, Zakowski PC, Kubak B, Pereira MR, Dhand A, **Kransdorf EP**, Stenehjem E, Schmidt M, Katugaha S, Stocks L, Delli Carpini KW, Fuentes JR, Kiros LS, Montgomery S. *Trypanosoma cruzi* infections in solid organ transplant recipients, 2014. *Open Forum Infectious Diseases* 2015.
29. **Kransdorf EP**, Loghmanpour NA, Kanwar MK, Temkit M, Stehlik J. Development of a clinical prediction model for cardiac allograft vasculopathy: comparison of three multivariate methods. *Journal of Heart and Lung Transplantation* 2016; 35 (4 Supplement): S98.
30. Vucicevic D, **Kransdorf EP**, Steidley DE, Vargas HE, Carey EJ. Vibration controlled transient elastography for identification of hepatic fibrosis in patients evaluated for cardiac transplantation or left ventricular assist device: A pilot study. *Journal of Heart and Lung Transplantation* 2016; 35 (4 Supplement): S210.
31. **Kransdorf EP**, Steidley DE, Pando M. Calculated panel reactive antibody predicts mortality on the heart transplant waiting list. Presented at the American Society of Transplantation “Cutting Edge of Transplantation” Meeting, Phoenix, Arizona. February 2016.
32. Murphy K, **Kransdorf EP**, Wilansky S, Pajaro OE, Steidley DE. Impact of size mismatch on heart transplant outcomes. *Journal of Heart and Lung Transplantation* 2016; 35 (4 Supplement): S214.
33. Staley LL, Schroedl L, Steidley DE, Scott R, Spadafore J, Amity ME, Boldea E, Lanza L, DeValeria P, Hardaway BW, **Kransdorf EP**, Pajaro O. Use of tissue plasminogen activator (tPA) to successfully treat HeartWare LVAD (HVAD) pump thrombosis. *Journal of Heart and Lung Transplantation* 2016; 35 (4 Supplement): S266.
34. McGrath B, Vucicevic D, **Kransdorf E**, Steidley D, Pajaro O, Carey E. Sarcopenia as a predictor of postoperative hospital stay in heart transplant recipients. *Journal of Heart and Lung Transplantation* 2016; 35 (4 Supplement): S296.
35. Louka B, **Kransdorf E**, Yang E, Lanza L, Pajaro O. Recurrent pericardial effusion in a heart transplant recipient managed with a PleurX catheter. *Cardiology* 2016; 134 (Supplement 1): 104.
36. David Chang, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Michele Hamilton, Dael Geft, **Evan Kransdorf**, Lawrence Czer, Jon Kobashigawa, Francisco Arabia, and Jaime Moriguchi. Does Socioeconomic Status Impact Outcome following Mechanical Circulatory Support Device Implantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S435–S436.
37. **Evan Kransdorf**, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Angela Velleca, Emily Stimpson, Dael Geft, David Chang, Lawrence Czer, Alfredo Trento, and Jon Kobashigawa. Predicted Heart Mass Is the Optimal Metric for Size Matching in Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S113–S114.

38. David Chang, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Angela Velleca, Gina Jamero, **Evan Kransdorf**, Dael Geft, Lawrence Czer, Fardad Esmailian, and Jon Kobashigawa. Is Tacrolimus/Proliferation Signal Inhibitor (PSI) Comparable to Cyclosporine/PSI After Heart Transplantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S303.
39. Jon Kobashigawa, Michelle Kittleson, Tamar Aintablian, Babak Azarbal, Antoine Hage, **Evan Kransdorf**, Dael Geft, David Chang, Lawrence Czer, Fardad Esmailian, Xiaohai Zhang, Nancy Reinsmoen, and Jignesh Patel. Only Persistent Donor Specific Antibodies Are Associated with Subsequent Cardiac Allograft Vasculopathy after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S292.
40. Jignesh Patel, Michelle Kittleson, Tamar Aintablian, Gabriel Esmailian, Angela Velleca, Antoine Hage, **Evan Kransdorf**, Dael Geft, David Chang, Lawrence Czer, and Jon Kobashigawa, 2017. Despite FDA Black Box Warning, Proliferation Signal Inhibitor (PSI) in the First Year with Induction Therapy Appears Safe in Heart Transplant Patients. *The Journal of Heart and Lung Transplantation*, 36(4), S303–S304.
41. David Chang, Michelle Kittleson, Tamar Aintablian, Lauren Arakawa, Gina Jamero, Dael Geft, **Evan Kransdorf**, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. Side Effects of Proliferation Signal Inhibitors Limit Their Practical Use After Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S301.
42. Jaime Moriguchi, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, James Kwan, **Evan Kransdorf**, Dael Geft, David Chang, Lawrence Czer, Jon Kobashigawa, and Francisco Arabia. Combined Heart-Kidney Transplant vs Heart Alone Transplant in Patients with Total Artificial Heart: Are they Viable? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S329.
43. David Chang, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Genevieve Rodriguez, Ryan Levine, Dael Geft, **Evan Kransdorf**, Lawrence Czer, Fardad Esmailian, and Jon Kobashigawa. Coronary Vasospasm after Heart Transplantation: Does it Portend Poor Outcome? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S294.
44. Dael Geft, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Ryan Levine, Michael Hashimoto, **Evan Kransdorf**, David Chang, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. The Story on Extracorporeal Membrane Oxygenation (ECMO) Directly to Mechanical Circulatory Support or to Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S336–S337.
45. Jon Kobashigawa, Nancy Reinsmoen, Xiaohai Zhang, Michelle Kittleson, Tamar Aintablian, Jennifer Krems, **Evan Kransdorf**, David Chang, Lawrence Czer, Fardad Esmailian, and Jignesh Patel. The Risk of Naïve vs Memory Patients Awaiting Heart Transplantation: Does It Make a Difference in Post-Transplant Outcomes? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S287–S288.
46. Dominick Megna, Fardad Esmailian, Jignesh Patel, Michelle Kittleson, Tamar Aintablian, Emily Stimpson, **Evan Kransdorf**, Dael Geft, David Chang, Lawrence Czer, and Jon Kobashigawa. Success for Combined Heart and Kidney Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S229.
47. Frank Liou, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Tina Kao, **Evan Kransdorf**, Dael Geft, David Chang, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. Donor Heart Diastolic Dysfunction: Do You Take This Heart for Transplantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S43.

48. Dael Geft, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Kristen Yabuno, Brenda Kearney, **Evan Kransdorf**, David Chang, Lawrence Czer, Alfredo Trento, and Jon Kobashigawa. Severe Tricuspid Regurgitation After Heart Transplantation: Does It Require Surgical Repair? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S223–S224.
49. **Kransdorf E**, Kittleson M, Patel J, Aintablian T, Levine R, Kearney B, Musto N, Hage A, Geft D, Czer L, Esmailian F, Trento A, Kobashigawa J. Risk of Amiodarone and Permanent Pacemaker Placement After Heart Transplantation. *Am J Transplant*. 2017;17 (suppl 3).
50. **Kransdorf E**, Aintablian T, Kittleson M, Patel J, Kobashigawa J. Validation of a Prediction Model for Cardiac Allograft Vasculopathy. *Am J Transplant*. 2017;17 (suppl 3).
51. Rafiei M, Moriguchi J, Kittleson M, Patel J, Aintablian T, Passano E, Sharoff R, Kwan J, **Kransdorf E**, Chang D, Czer L, Kobashigawa J, Arabia F. Does the Model for End Stage Liver Disease (MELD) Score Predict Outcome in Total Artificial Heart Patients? *Am J Transplant*. 2017;17 (suppl 3).
52. D.H. Chang, M. Kittleson, J. Patel, T. Aintablian, R. Levine, D. Geft, **E. Kransdorf**, L. Czer, A. Trento, F. Esmailian, J.A. Kobashigawa. Treatment of Primary Graft Dysfunction with Plasmapheresis Improves Outcome. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S147.
53. **E. Kransdorf**, J. Patel, X. Zhang, M. Pando, M. Kittleson, L. Czer, D. H. Chang, S. Dimbil, R. Levine, K. Norland, M. Hamilton, J. Chung, J. A. Kobashigawa. Novel Methods for Assessing Response to Desensitization. *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S439.
54. J. Patel, M. Kittleson, L. Czer, D. H. Chang, **E. Kransdorf**, S. Dimbil, R. Levine, S. Sana, M. Hamilton, F. Esmailian, D. Luthringer, J. A. Kobashigawa. The Risk of pAMR 1H after Heart Transplantation: Is it Bad? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S52.
55. M. Kittleson, J. Patel, L. Czer, D. H. Chang, **E. Kransdorf**, S. Dimbil, R. Levine, J. Davis, M. Hamilton, A. Trento, X. Zhang, J. A. Kobashigawa. The Clinical Impact of Early vs Late HLA Donor-Specific Antibody Development After Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S438.
56. J. Patel, M. Kittleson, L. Czer, D. H. Chang, S. Dimbil, R. Levine, A. Velleca, **E. Kransdorf**, M. Hamilton, A. Trento, J. A. Kobashigawa. Epstein-Barr Virus Mismatch (Donor+/Recipient-): Is Cancer the Only Risk? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S355.
57. R. Levine, J. Patel, M. Kittleson, L. Czer, D. Chang, **E. Kransdorf**, S. Dimbil, B. Kearney, D. Ramzy, F. Esmailian, J. A. Kobashigawa. Does a Redo Heart Transplant Decrease the Change for Primary Graft Dysfunction? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S349-350.
58. T. Kao, A. Velleca, J. Patel, M. Kittleson, L. Czer, S. Dimbil, R. Levine, A. Sanford, B. Kearny, **E. Kransdorf**, D. H. Chang, J. A. Kobashigawa. Does Occupation Affect Outcome Following Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S350-351.
59. **E. Kransdorf**, D. H. Chang, K. Nguyen, T. Tran, A. Patel, R. Levine, S. Dimbil, J. Patel, D. Ramzy, J. A. Kobashigawa. Liver Fibrosis Predicts Survival After Heart Transplant. *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S420-421.
60. R. Sharoff, J. Patel, M. Kittleson, L. Czer, R. Levine, S. Dimbil, N. Musto, D.H. Chang, **E. Kransdorf**,

- A. Trento, J.A. Kobashigawa. Jehovah Witness Patients: Should We Liberalize Criteria for Heart Transplantation? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S434.
61. M. Rafiei, J. Patel, M. Kittleson, L. Czer, D.H. Chang, S. Dimbil, R. Levine, **E. Kransdorf**, A. Hage, F. Esmailian, J.A. Kobashigawa. Older Donors Into Older Recipients: Still Contentious But Reasonable. *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S50-51.
  62. J. Patel, M. Kittleson, L. Czer, D.H. Chang, **E. Kransdorf**, S. Dimbil, R. Levine, S. Sana, M. Hamilton, F. Esmailian, D. Luthringer, J.A. Kobashigawa. The Risk of pAMR 1H After Heart Transplantation: Is It Bad? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S52.
  63. J. Patel, M. Kittleson, L. Czer, D.H. Chang, **E. Kransdorf**, S. Dimbil, R. Levine, K. Norland, A. Hage, D. Ramzy, J.A. Kobashigawa. Does ATG Induction Prevent Donor-specific Antibodies After Heart Transplantation? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S439.
  64. T. Sato, B. Azarbal, R. Cheng, M. Kittleson, J. Patel, L. Czer, R. Levine, S. Dimbil, T. Kao, **E. Kransdorf**, J.A. Kobashigawa. Combined Heart and Kidney Transplantation - Is There a Protective Effect Against Cardiac Allograft Vasculopathy Using Intravascular Ultrasound? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S411.
  65. J.A. Kobashigawa, J. Patel, M. Kittleson, L. Czer, D.H. Chang, **E. Kransdorf**, S. Sana, R. Levine, S. Dimbil, D. Luthringer, J. Yee, R. Woodward, P. Halloran. Donor-derived Cell Free DNA Correlates More Closely With Intra-graft mRNA Transcripts Rather Than Pathology Read Biopsies. *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S198.
  66. M. Kittleson, J. Patel, L. Czer, D.H. Chang, S. Dimbil, R. Levine, R. Bleiker, **E. Kransdorf**, F. Esmailian, X. Zhang, J.A. Kobashigawa. Is the Luminex 1:8 Dilution Truly the Poor Man's C1q for Patients Awaiting Heart Transplantation? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S438.
  67. J. Patel, M. Kittleson, L. Czer, D. Geft, S. Dimbil, R. Levine, B. Kearney, **E. Kransdorf**, F. Esmailian, J.A. Kobashigawa. In Sensitized Pre-Transplant Patients, Does IVIG after Heart Transplant Have any Benefit? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S440.
  68. A. Velleca, M. Kittleson, J. Patel, L. Czer, D.H. Chang, **E. Kransdorf**, S. Dimbil, R. Levine, S. Mersola, M. Curry, J. Chung, J.A. Kobashigawa. Use of "Needle in the Arm" Donors for Urgent Status Recipients in Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S343-344. *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S368-369.
  69. S. Dimbil, J. Patel, M. Kittleson, L. Czer, D.H. Chang, **E. Kransdorf**, R. Levine, J. Baker, R. Bleiker, F. Esmailian, J.A. Kobashigawa. Older Kidney Donors in Dual Heart-Kidney Transplantation: How Do They Stack Up? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S352-353.
  70. A. Nikolova, J. Patel, M. Kittleson, L. Czer, R. Levine, S. Dimbil, D.H. Chang, **E. Kransdorf**, J. Chung, J.A. Kobashigawa. Length of Time on Left Ventricular Assist Device Prior to Heart Transplant: Does it Affect Outcome? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S368-369.
  71. M. Kittleson, J. Patel, L. Czer, D.H. Chang, **E. Kransdorf**, R. Levine, S. Dimbil, A. Shen, A. Trento, R. Zabner, P. Zakowski, J.A. Kobashigawa. Multi-Drug Resistant Infection after Heart Transplantation: How Serious is This? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S356.



72. **E. Kransdorf**, J. Patel, M. Kittleson, L. Czer, D. Chang, S. Dimbil, R. Levine, A. Hsu, T. Davis, K. Norland, A. Trento, J.A. Kobashigawa. Does a History of Malignancy Prior to Heart-transplant Increase Post-transplant Risk? *The Journal of Heart and Lung Transplantation*, 2018. 37(4), S421.
73. Lillian Benck, MD, **Evan Kransdorf**, MD, PhD, Michelle Kittleson, MD, PhD, Joshua Chung, MD, Fardad Esmailian, MD, and Jon Kobashigawa, MD. Predicted Heart Mass and Organ Offer Turn-Down in Heart Transplant. *Circulation*. 2018;138: A16868
74. J.A. Kobashigawa, J. Patel, M. Kittleson, **E. Kransdorf**, S. Dimbil, R. Levine, G. Esmailian, C. Kawata, L. Czer, M. Hamilton, D. Ramzy, X. Zhang. Non-HLA Antibodies as a Cause for Biopsy Negative Rejection: Is It Worth Testing for Them? *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S87.
75. M Kittleson, J. Patel, D. H. Chang, **E. Kransdorf**, S. Dimbil, K. Yabuno, B. Kearney, L. Czer, M. Hamilton, F. Esmailian, J. A. Kobashigawa. Is Amiodarone Truly a Risk Factor for Primary Graft Dysfunction? *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S268.
76. **E. Kransdorf**, M. Kittleson, J. Patel, R. Cole, S. Dimbil, R. Levine, M. Olymbios, T. Kao, L. Czer, B. Azarbal, J. Chung, J. A. Kobashigawa. Mixed Rejection: More Important Than Thought after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S388.
77. J. A. Kobashigawa, M. Kittleson, D. H. Chang, **E. Kransdorf**, S. Dimbil, R. Levine, C. Kawata, M. Olymbios, A. Velleca, L. Czer, X. Zhang, D. Ramzy, J. Patel. Crossing Low Level Donor-Specific Antibody at the Time of Heart Transplantation May Save Lives. *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S88.
78. J.A. Kobashigawa, M. Kittleson, D.H. Chang, **E. Kransdorf**, S. Dimbil, R. Levine, C. Kawata, M. Olymbios, A. Velleca, L. Czer, X. Zhang, D. Ramzy, J. Patel. Short and Stout Female Donors in Heart Transplantation: Do They Make a Difference? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S88.
79. A. Wolfson, D. Chang, S. Bannykh, M. Kittleson, **E. Kransdorf**, J. Kobashigawa. End-Stage Cardiomyopathy Due to Hydroxychloroquine Therapy. *The Journal of Heart and Lung Transplantation*, 2019; 38(4).
80. J. A. Kobashigawa, M.Kittleson, D. H. Chang, **E. Kransdorf**, R. Levine, S. Dimbil, C. Kawata, M. Olymbios, A.Velleca, L.Czer, X.Zhang, J.Chung, J.Patel. The Impact of Complement-Binding Donor-Specific Antibodies on Adverse Events Long-Term after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S144.
81. J. A. Kobashigawa, J. Patel, **E. Kransdorf**, D. Chang, M. Kittleson, S. Dimbil, R. Levine, S. Sana, A. Wolfson, L. Czer, M. Hamilton, R. Woodward, F. Esmailian. Does Cell-Free DNA Detect the Development of De Novo Donor Specific Antibodies. *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S288.
82. J. Patel, M. Kittleson, D. Chang, **E. Kransdorf**, S. Dimbil, R. Sharoff, L. Czer, A. Hage, F. Esmailian, J. A. Kobashigawa. Heightened Immune Response in Heart Transplant Patients Surviving Severe Primary Graft Dysfunction. *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S294.
83. J. Patel, M. Kittleson, R. Levine, S. Sana, A. Shen, D. Geft, B. Azarbal, **E. Kransdorf**, J. Kobashigawa. Heart Transplantation for Cardiac Amyloidosis - Worthwhile? *The Journal of Heart and Lung*

Transplantation, 2019. 38(4), S215.

84. J. Patel, M. Kittleson, D. Chang, **E. Kransdorf**, R. Levine, S. Dimbil, T. Kao, L. Czer, R. Cole, F. Esmailian, J. Kobashigawa. 5-Year Outcome of Photopheresis in Heart-Transplantation with Refractory/Persistent Rejection. *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S276.
85. **E. Kransdorf**, J. Patel, M. Kittleson, D.H. Chang, R. Levine, S. Dimbil, A. Bitterman, A. Velleca, L. Czer, J. Moriguchi, F. Esmailian, J.A. Kobashigawa. Does Antibody-Mediated Rejection in the First-Month after Heart Transplant Lead to Poor Longer-Term Outcome? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S292.
86. D. H. Chang, J. Patel, M. Kittleson, **E. Kransdorf**, S. Dimbil, R. Levine, T. Kao, T. Hage, L. Czer, A. Hage, A. Trento, J. A. Kobashigawa. Is There a Benefit of Metformin after Heart Transplantation? *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S276.
87. L. Czer, M. Kittleson, J. Patel, **E. Kransdorf**, R. Levine, S. Dimbil, R. Sharoff. B. Kearney, D. H. Chang, M. Hamilton, F. Esmailian, J. A. Kobashigawa. 10-Year Outcomes in Heart-Kidney Transplant Patients: Is There a Protective Effect for the Donor Heart? *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S217.
88. E. Kransdorf, J. Patel, M. Kittleson, D. Chang, S. Dimbil, R. Levine, A. Shen, A. Jain, M. Olymbios, L. Czer, X. Zhang, J. Kobashigawa. What Antigens to Avoid in Heart Transplant to Optimize Outcome via the Virtual Crossmatch. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S264.
89. L. Benck, **E. Kransdorf**, J. Patel, D. Malinoski, R. Levine, C. Neimann, J.A. Kobashigawa. Achievement of Donor Management Goals and Primary Graft Dysfunction after Heart Transplant. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S268.
90. M. Kittleson, J. Patel, D.H. Chang, **E. Kransdorf**, R. Levine, S. Dimbil, K. Nishihara, T. Kao, L. Czer, A. Hage, J. Chung, J.A. Kobashigawa. Donor Left Ventricular Hypertrophy: Over-Rated or Does Donor History of Hypertension Make a Difference for Post-Heart Transplant Outcome? *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S269.
91. M. Kittleson, J. Patel, **E. Kransdorf**, D. Geft, S. Dimbil, R. Levine, A. Velleca, L. Czer, A. Hage. R. Zabner, P. Zakowski, J. Kobashigawa. Undue Infection Risk from Proliferation Signal Inhibitors When Initiated Later after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S311.
92. A. Wolfson, M. Kittleson, J. Patel, **E. Kransdorf**, R. Cole, S. Dimbil, A. Lam, L. Czer, A. Hage, J. Chung, J. Moriguchi, J. A. Kobashigawa. Biopsy-Negative Rejection Late after Heart Transplantation: Long-Term Outcome. *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S287-288.
93. R. Levine, J. Patel, M. Kittleson, D. Geft, **E. Kransdorf**, S. Dimbil, E. Passano, S. Sana, L. Czer, A. Hage, D. Ramzy, J. A. Kobashigawa. Does the Model for End-Stage Liver Disease Predict Primary Graft Dysfunction? *The Journal of Heart and Lung Transplantation*, 2019. 38(4), S297.
94. **Evan Kransdorf**, Robert Cole, Jaime Moriguchi, Joshua Chung, Danny Ramzy, Jignesh Patel, Fardad Esmailian and Jon Kobashigawa. Turn-Down For Donor Age and Size Has Increased For Heart Transplant Candidates With Mechanical Circulatory Support. *Journal of the American College of Cardiology*, 2019. 73(9), S1.

95. Robert J.H. Miller, Andriana Nikolova, Alan Kwan, Ryan Levine, Sadia Dimbil, Jon Kobashigawa, **Evan Kransdorf**, Jignesh Patel, Louise Thomson, Debiao Li, Daniel Berman, Balaji Tamarappoo. Multiparametric Cardiac Magnetic Resonance Phenotyping Of Patients With A History of Cardiac Transplant Rejection. *Journal of American College of Cardiology*, 2019. 73(9), S1.
96. **Kransdorf E**, Patel J, Dimbil S, Levine R, Chang DH, Kobashigawa JA. What is the post-heart transplant risk of infectious complications from pre-transplant desensitization therapy? *American Journal of Transplantation*. 2019; 19:786.
97. Kittleson M, Patel J, Chang DH, **Kransdorf E**, Dimbil S, Levine R, Yabuno K, Czer L, Hamilton M, Esmailian F, Kobashigawa JA. Amiodarone and primary graft dysfunction in heart transplantation: reality or myth? *American Journal of Transplantation*. 2019; 19:774-5.
98. Kittleson M, Patel J, **Kransdorf E**, Dimbil S, Levine R, Kobashigawa JA. Outcome of late biopsy-negative rejection after heart transplantation. *American Journal of Transplantation*. 2019; 19:771-2.
99. Shah K, Levine RJ, Dimbil S, Sana S, Halloran PF, Patel J, Chang DH, **Kransdorf E**, Kittleson M, Kobashigawa JA. Prevalence of Donor Specific Antibody in Heart Transplant Recipients with Antibody-Mediated Rejection as Compared to Abnormal Intra-graft mRNA Transcripts by Molecular Microscope System. *Am J Transplant*. 2019; 19 (suppl 3).
100. Lor K, **Kransdorf E**, Patel J, Kittleson M, Chang D, Kobashigawa JA. Anemia and Hemolysis on Dapsone Despite Normal Glucose-6-Phosphate Dehydrogenase Activity in Heart Transplant Recipients. *Am J Transplant*. 2019; 19 (suppl 3).
101. Patel J, **Kransdorf E**, Levine R, Dimbil S, Czer L, Kobashigawa JA. Does the Type of Pre-Heart Transplant Desensitization Therapy Affect 5-Year Post-Transplant Outcomes? *Am J Transplant*. 2019; 19 (suppl 3).
102. Aguilar J, Patel J, Kittleson M, Chang DH, **Kransdorf E**, Shen A, Nishihara K, Czer L, Kobashigawa JA. Outcomes of Hearts Transplanted From  $\geq 60$  Year-old Donors. *J Am Coll Cardiol*. 2020 Mar 24;75(11 S1):814.
103. Nguyen V, **Kransdorf E**, Patel J, Nishihara K, Levine R, Sumbi C, Kobashigawa JA. Predictors of Delayed Renal Graft Function in Combined Heart and Kidney Transplant Recipients. *J Heart Lung Transplant*. 2020 Apr;39(4):S271.
104. Emerson D, Megna D, Cole R, Levine R, Esmailian F, Chikwe J, Trento A, Ramzy D, **Kransdorf E**, Kobashigawa JA. Does Brain Death Related to Underlying Donor Disease Correlate with Adverse Outcomes after Heart Transplant? *J Heart Lung Transplant*. 2020 Apr;39(4):S266.
105. Patel J, Kittleson M, **Kransdorf E**, Chang DH, Czer L, Shen A, Nishihara K, Sharoff R, Hamilton M, Esmailian F, Kobashigawa JA. The Natural History of Pre-Existing Donor Specific Antibody and Amnestic Responses after Heart Transplantation. *J Heart Lung Transplant*. 2020 Apr;39(4):S29.
106. Patel J, Kittleson M, **Kransdorf E**, Shen A, Nishihara K, Jamero G, Azarbal B, Hage A, Czer L, Megna D, Kobashigawa JA. Does the Development of Donor Specific Antibody after Heart Transplantation Depend on the Presence or Absence of Corticosteroids as Maintenance Therapy? *J Heart Lung Transplant*. 2020 Apr;39(4):S273.

107. Kittleson M, Patel J, Chang DH, **Kransdorf E**, Shen A, Nishihara K, Melamed D, Jamero G, Azarbal B, Czer L, Ramzy D, Trento A, Kobashigawa JA. Outcome of Right Ventricular Primary Graft Dysfunction after Heart Transplantation. *J Heart Lung Transplant*. 2020 Apr;39(4):S298.
108. Aiken A, Patel J, **Kransdorf E**, Shen A, Nishihara K, Velleca R, Cole R, Hamilton M, Czer L, Megna D, Zhang X, Kobashigawa JA. Donor Specific Antibodies after Heart Transplantation: Can They Be Treated? *J Heart Lung Transplant*. 2020 Apr;39(4):S240.
109. Kittleson M, Patel J, **Kransdorf E**, Shen A, Nishihara K, Rajkumar S, Velleca A, Geft D, Czer L, Moriguchi M, Kobashigawa JA. Desensitization Therapy for Mechanical Circulatory Support Patients with Existing Driveline Infection: Is It Safe with Current Desensitization Therapies? *J Heart Lung Transplant*. 2020 Apr;39(4):S446.
110. Kittleson M, Patel J, **Kransdorf E**, Shen A, Nishihara K, Jamero G, Sana S, Hage A, Czer L, Esmailian F, Kobashigawa JA. Is Anti-Thymocyte Globulin for Sensitized Patients Undergoing Heart Transplantation Effective? *J Heart Lung Transplant*. 2020 Apr;39(4):S226.
111. Kobashigawa JA, Kittleson M, Chang DH, **Kransdorf E**, Shen A, Nishihara K, Jamero G, Coleman B, Czer L, Ramzy D, Esmailian F, Patel J. Post-Heart Transplant Outcomes of Sensitized Patients Who Have Undergone Desensitization Therapy. *J Heart Lung Transplant*. 2020 Apr;39(4):S275.
112. Nishihara K, Patel J, Kittleson M, Chang D, **Kransdorf E**, Geft D, Shen A, Czer L, Esmailian F, Kobashigawa JA. Do the Characteristics of Donor Specific Antibody Truly Predict Severity of Cardiac Allograft Vasculopathy Late After Heart Transplantation? *Am J Transplant*. 2020; 20 (Supplement 3).
113. Kobashigawa JA, Kittleson M, Patel J, Chang D, **Kransdorf E**, Geft D, Nishihara K, Shen A, Czer L, Esmailian F. High-risk Antibodies Pre-transplant Impact Outcome After Heart Transplantation. *Am J Transplant*. 2020; 20 (Supplement 3).
114. Shen A, Patel J, Kittleson M, Chang D, **Kransdorf E**, Geft D, Nishihara K, Czer L, Esmailian F, Kobashigawa JA. The Frequency of De Novo Donor Specific Antibody in the Years Following Heart Transplantation. *Am J Transplant*. 2020; 20 (Supplement 3).
115. Patel J, Kittleson M, Chang D, **Kransdorf E**, Geft D, Shen A, Nishihara K, Velleca A, Czer L, Esmailian F, Kobashigawa JA. Is Ischemia Reperfusion Injury Immediately After Heart Transplantation Correlated to Increased Intimal Thickening in the First Year? *Am J Transplant*. 2020; 20 (Supplement 3).
116. Kittleson M, Patel J, Chang D, **Kransdorf E**, Geft D, Nishihara K, Shen A, May B, Czer L, Esmailian F, Kobashigawa JA. Is 3-4+ Liver Fibrosis a Contraindication to Heart Transplantation? *Am J Transplant*. 2020; 20 (Supplement 3).
117. Kittleson M, Patel J, Chang D, **Kransdorf E**, Geft D, Nishihara K, Shen A, Velleca A, Czer L, Esmailian F, Kobashigawa JA. Challenging Dogma that Anti-thymocyte Globulin Induction with Delated Calcineurin Inhibitor Benefits Patients with Renal Insufficiency Undergoing Heart Transplant. *Am J Transplant*. 2020; 20 (Supplement 3).
118. Patel J, Kittleson M, Chang D, **Kransdorf E**, Geft D, Shen A, Nishihara K, Jamero G, Czer L, Esmailian F, Kobashigawa JA. Effects of Donor Heavy Alcohol Use on Post-heart Transplant Outcomes: Time to Abstain? *Am J Transplant*. 2020; 20 (Supplement 3).